drugset / Trial / NCT00899431
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
RandomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if lenalidomide, when given with a stem cell transplant and chemotherapy (bendamustine, fludarabine, and rituximab), can help to control CLL. The safety of this treatment combination will also be studied.
Timeline
- Start
- 2009-05-06
- Primary completion
- 2018-10-07
- Completion
- 2018-10-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lenalidomide | Other / unclassified | 5 mg | Oral |
| Comparator | Allopurinol | Small molecule | 300 mg | Oral |
| Comparator | Bendamustine | Small molecule | 130 mg/m2 | Intravenous |
| Comparator | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |
| Comparator | Rituximab | Monoclonal antibody | 1000 mg/m2 | Intravenous |
| Comparator | Thymoglobulin | Protein / enzyme biologic | 1 mg/kg | Intravenous |